Cargando…

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment of ALK+ patients. However, lorlatinib-induced resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jóri, Balázs, Falk, Markus, Hövel, Iris, Weist, Peggy, Tiemann, Markus, Heukamp, Lukas C., Griesinger, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497554/ https://www.ncbi.nlm.nih.gov/pubmed/36135089 http://dx.doi.org/10.3390/curroncol29090520

Ejemplares similares

Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2021)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023)

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib
por: Roeper, Julia, et al.
Publicado: (2022)

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
por: Frost, Nikolaj, et al.
Publicado: (2021)

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
por: Schatz, Stefanie, et al.
Publicado: (2020)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance
por: Sakamoto, Mandy, et al.
Publicado: (2023)

2032 primera misión tripulada a marte
por: Cooper, M. G. Cooper, Michael George

Cancer Mortality Projections in Korea up to 2032
por: Son, Mia, et al.
Publicado: (2016)

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
por: Katayama, Ryohei, et al.
Publicado: (2019)

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
por: Roeper, Julia, et al.
Publicado: (2020)

Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation
por: Dimou, Anastasios, et al.
Publicado: (2019)

GEO-3 scenarios 2002-2032 : quantification and analysis of environmental impacts /
Publicado: (2004)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1(G2032R) and ALK(G1202R)
por: Liu, Siming, et al.
Publicado: (2023)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)

P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape
por: Sun, Huiyong, et al.
Publicado: (2014)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Forecasting Cause-Specific Mortality in Korea up to Year 2032
por: Yun, Jae-Won, et al.
Publicado: (2016)

2032. First National Survey of Antimicrobial and Antifungal Stewardship in Japan
por: Moriyama, Yuki, et al.
Publicado: (2019)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain
por: Chen, Wei, et al.
Publicado: (2020)

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
por: Li, Huihui, et al.
Publicado: (2023)

Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report
por: Li, Dan, et al.
Publicado: (2022)

Synthesis and preliminary PET imaging of (11)C and (18)F isotopologues of the ROS1/ALK inhibitor lorlatinib
por: Collier, Thomas Lee, et al.
Publicado: (2017)

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
por: Girard, N., et al.
Publicado: (2022)

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
por: Willing, Eva-Maria, et al.
Publicado: (2023)

Implementation priority and timeline of possible cost saving measures for the period 2024-2032
Publicado: (2023)

Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032
por: Carter, Lisa L, et al.
Publicado: (2022)

Radiology Education and Training 2022–2032: Are We in Danger of Fighting Yesterday’s War?
por: Rowe, Steven P., et al.
Publicado: (2023)

Liquid biopsy and glioblastoma
por: Eibl, Robert H., et al.
Publicado: (2023)

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
por: Schneider, Jaime L., et al.
Publicado: (2022)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Medicine 2032: The future of cardiovascular disease prevention with machine learning and digital health technology
por: Javaid, Aamir, et al.
Publicado: (2022)

Trends in hospitalization of patients with diabetes mellitus in Ghana from 2012 to 2017 with predictions to 2032
por: Narh, Clement T, et al.
Publicado: (2021)

Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
por: Nakamura, Tomomi, et al.
Publicado: (2018)

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ktf37qv10riifagkmod56fn88m